That Biotech M&A Wave? More like a Trickle


Large cap biotech companies held a number of meetings with analysts and investors to discuss their plans for 2018, while both Celgene and Regeneron pre-announced 2017 results that were in-line to positive, compared to consensus estimates. Leerink's Geoffrey Porges and Bradley Canino take a look at the week in biotech, writing that Celgene and Regeneron were "predictably cautious" in their guidance, while the sector largely declined to estimate how tax changes will affect their profits just yet, although most companies have said that the tax bill is mostly positive.



from Biotech News